Human beings have grappled with the phenomenon of growing old ever since they first consciously became aware of it. While people today can expect to live longer lives than at any time in history, aging often brings many challenges that must be confronted.
A company founded by noted technology and healthcare entrepreneur Jim Plante aims to afford relief to millions of older people. By using advanced biotechnology to mimic the effects of a naturally occurring protein, Klotho Therapeutics hopes to turn back the hands of time for many patients.
A Protein That Has Been Implicated in Many Aging-Related Processes
Aging is not a single, cohesive phenomenon, but rather a collective name given to dozens of distinct processes that happen as the human body grows older. In many of these individual cases, however, the presence of a protein that researchers have dubbed “Klotho” helps slow down or even reverse the damage and deterioration so typical of aging.
First identified in laboratory settings in 1997, Klotho has since been studied in dozens of clinical trials. From its ability to prevent or even cure diseases that are more common in older people to how it addresses particular symptoms of aging, Klotho has come to seem to some like a true fountain of youth.
Naturally enough, interest in how to leverage such findings concretely has been rising steadily with every new discovery. Klotho Therapeutics was founded to research and bring to market safe, effective ways of mimicking the effects of this protein.
A Commitment to Helping People Everywhere Fight Back Against Aging
Toward that end, Klotho Therapeutics has laid out an aggressive but strategic timetable. With a stated goal of minimizing the time it will take to begin human trials, Klotho Therapeutics has already taken great strides toward that milestone.
In order to make such rapid progress, the company will first focus on one especially well-documented effect of the protein Klotho. That will see researchers assessing how well its proprietary approach might replicate Klotho’s amply established ability to slow down certain types of aging-related kidney disease. Although the first trial has yet to begin, the company’s representatives have so far signaled confidence that it will remain on schedule in every respect.